DDInter255 DDInter1293
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Nilotinib
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nilotinib
Busulfan {u} (Compound) upregulates {v} (Gene) SOCS2
SOCS2 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Busulfan {u} (Compound) downregulates {v} (Gene) TNIP1
TNIP1 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Busulfan {u} (Compound) downregulates {v} (Gene) BNIP3
BNIP3 {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Busulfan {u} (Compound) causes {v} (Side Effect) Anxiety
Anxiety {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Busulfan {u} (Compound) upregulates {v} (Gene) EPHA3
EPHA3 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) PDGFRB
PDGFRB {u} (Gene) is bound by {v} (Compound) Nilotinib
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Busulfan {u} (Compound) upregulates {v} (Gene) SOCS2
SOCS2 {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib (Compound)
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Busulfan (Compound) upregulates SOCS2 (Gene) and SOCS2 (Gene) is upregulated by Nilotinib (Compound)
Busulfan (Compound) downregulates TNIP1 (Gene) and TNIP1 (Gene) is upregulated by Nilotinib (Compound)
Busulfan (Compound) downregulates BNIP3 (Gene) and BNIP3 (Gene) is downregulated by Nilotinib (Compound)
Busulfan (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Busulfan (Compound) upregulates EPHA3 (Gene) and EPHA3 (Gene) is bound by Nilotinib (Compound) and EPHA3 (Gene) is upregulated by Nilotinib (Compound)
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with PDGFRB (Gene) and PDGFRB (Gene) is bound by Nilotinib (Compound)
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Busulfan (Compound) upregulates SOCS2 (Gene) and SOCS2 (Gene) is upregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib